VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc AZN to jointly develop ...
Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...
Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in ...
A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine ...
The development of cancer is not a process triggered immediately by the emergence of an oncogenic mutation. There is growing ...
Treatment sequencing in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains a major unmet clinical need.1 Although somatostatin receptor-positive, well differentiated GEP-NETs ...
Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results